Eli Lilly's Rajiv Gulati on Prospects in India and China

Knowledge at Wharton

Ask about Knowledge at Wharton

Episode Description

India's huge potential pharmaceutical market and wealth of industry talent means it will be strategically critical for multinationals in the years ahead, notes Rajiv Gulati, director of India-China strategy and corporate strategic planning for Eli Lilly. But weak intellectual property protection continues to hold the country back by hampering innovation, he says. In China, there may be even greater potential, but huge regulatory barriers block a clear path. Gulati spoke with India Knowledge@Wharton about these and other industry issues during the 2008 Wharton India Economic Forum.

Read the full transcriptHide the full transcript
  1. this podcast is brought to you by Indian knowledge at Warton please visit knowledge. won. up.edu India for more
  2. information India imagine was the theme of the 2008 Wharton India economic Forum
  3. that was held in Philadelphia recently the dayong event attracted several leaders including apj Abdul Kalam former
  4. president of India as well as CEOs of Indian companies nonprofit groups Consulting and private Equity firms
  5. Indian knowledge at Wharton brings you one-on-one conversations with these leaders we're speaking with Rajiv gulati
  6. who is director for China India strategy at Eli lilan company today uh thanks very much for joining us it's a pleasure
  7. to be here uh Rajiv uh what what was behind Eli Lily's joint venture with Ramba in the 1990s I understand that you
  8. joined Eli Lily from Ram ta around that time uh when the companies uh formed this joint venture so what was the basis
  9. for that okay uh let me talk from Lily side because that was your uh question U for a long time Lily had been
  10. a Midwest base a conservative pharmaceutical company where us was the biggest market so it used to be us and
  11. ous business which was much smaller and I would say the culture of the company changed when the new chairman Randy
  12. tobas has uh joined from AT&T and he was head of international business and he believed that there is growth outside
  13. the US and that was the time that Lily started operating in China Indonesia India Bangladesh Sri Lanka and
  14. many countries in in Asia where it was never never present and when Lily was starting in
  15. India India just started liberalizing and it was the business environment was still tough and it's a difficult Market
  16. too the distribution for example there are 271 cities with more than 100,000 population now how do you reach them uh
  17. to go in as a new company and set up distribution all the regulatory approvals uh the manufacturing needs
  18. which were there those times it's not easy uh that's where the partnership with renxi made sense renxi was at that
  19. time the largest uh Indian company uh operating in India IND and that's where the partnership came about which really
  20. facilitated uh Lily's entry into the Indian market okay well now uh companies like Rami and Dr reedy's are challenging
  21. drugs that are going off patent so how uh how how is a company like El Lily protecting itself from that
  22. Trend um see this these challenges have been there will be there so you protect your
  23. yourself legally so question is not so much how multinationals or multinationals like Lily protect
  24. themselves I I think there's a very uh strange question that Indian companies are struggling with on one side uh the
  25. patents have been reintroduced into India and all large Indian companies want to become Innovative pharmaceutical
  26. companies with their own patents on the other side they have this huge generic business which is profitable which is
  27. global that's where they are uh you know fighting lawsuits with the multinationals for the for the patents
  28. so to go off to so that they can sell their generics now how do they make transition from a very large generic
  29. company to becoming Innovative so I think that that's a challenge they are facing multinationals will have these
  30. challenges a given because patents have a limited life uh when the patents are challenged there is a six months
  31. exclusivity that's where generics make most of the profit because after that it's a commodity where the profit is
  32. much less uh so that's a business model that all generic companies have worldwide in fact there is a company in
  33. the US and one year I think it made more profit by out of court settlements than by selling generics so
  34. that's a business model that was operating in the US for a long time and now Indian companies are following the
  35. same one what would you say are sort of a primary deterrence of in Innovation or
  36. maybe the primary hurdles for innovation in the pharmaceutical industry in India
  37. if there are uh everybody talks about intellectual property protection intellectual property protection is a
  38. reward for Innovation if you don't have adequate protection it does not reward Innovation and it hampers Innovation and
  39. that's what uh on behalf of Lily and other companies even as an Indian I have been talking to the Indian government uh
  40. that you cannot have research and investment in research within the country unless you have adequate
  41. safeguards to protect intellectual property now how how does Eli L's strategy for China differ from its
  42. strategy for India China is one of the fastest growing pharmaceutical markets in the
  43. world it's already moved from the 12th largest to being eighth or ninth largest in next 5 years it will be the fifth
  44. largest and by 2020 or 2025 this will be the second largest pharmaceutical Market
  45. in the world overtaking Japan and just second to the US so such a large and attractive
  46. Market uh demands investment a comprehensive presence uh please remember that in China it's it's
  47. centralized uh even the courts reporting to the government at one time the pharmaceutical factories in China used
  48. to report to the FDA equivalent in China which is a very strange situation and therefore when you are dealing with the
  49. government you're working with them and they want comprehensive presence too so all your regulatory approvals your
  50. pricing situation your intellectual property they're all linked with one central power so you work with that with
  51. that Authority and for sales marketing investment in manufacturing investment in R&D it's all linked and part of one
  52. large business uh process to have a comprehensive presence in a large Market whereas in India the local industry is
  53. extremely strong because of lack of patents for the last uh 35 years or more and in that market to compete even today
  54. at low prices and very high volumes is not a model which multinationals have perfected yet therefore India has much
  55. more to offer because of their local industry strength and highly educated uh scientific pool of talent as a source
  56. for conducting clinical trials for conducting Discovery research uh I would say for formulation devel velopment
  57. chemical research and so on so I would say India is far more important can add far more value by Outsourcing research
  58. and other services to that country whereas China adds much more value as a market and that demands comprehensive
  59. presence so the you need to look at these two significantly differently very separately how uh what what significant
  60. um Trends do you see on the horizon for the pharmaceutical pharmaceutical industry pharmaceutical
  61. industry worldwide is a huge challenge all of us know that uh large patents are expiring and if you look at the quantum
  62. uh we are talking of something like between 50 to 100 billion dollar worth of patents expiring in three or four
  63. years remember this is a $600 billion industry worldwide so one sixth of the global sales or more importantly 1/4 of
  64. the Us sales for large pharmaceutical companies will vanish in next 3 to four years that's one challenge uh Second
  65. Challenge is the rising cost of health care which most developed countries cannot afford in the US we have 15 to
  66. 16% of GDP being spent on Healthcare uh in in in Europe in Australia in Canada government pays for
  67. healthcare and they are broke too and all across the developed World Japan Europe even the US population is aging
  68. now aging population means less productive people contributing to the pool and more people using the healthcare
  69. services which insurance companies of the government has to pay for which means that some kind of a control on
  70. costs which will include pharmaceutical industry either the uh the pressure on prices or in Europe it's very difficult
  71. to get new products on the formulary where government reimburses so you have government pressures you have challenges
  72. of uh patents expiring and the third thing is FDA because of the recent happenings it's become very very strong
  73. trict in approving new molecules if you look at the trend the new molecules approved by FDA every year has been
  74. falling so you have patents going off you cannot replace this with new products and you have pressures on cost
  75. uh and formulary or the excess worldwide now this is a challenge all multinationals are facing and it's a
  76. very very difficult time uh for the industry as a global industry evolves do you think that the differences between
  77. these markets are going to disappear just give you a small number in the US today 70% prescriptions that are written
  78. are of generics so by volume that's already a very large market and those models have been operating uh always
  79. it's it's the 30% prescriptions of patented which have most of the value because the price difference is huge uh
  80. which is under a huge threat going forward right and do you think that it's still going to be an issue going forward
  81. uh reaching reaching population in India um it sounds you said you originally said that there was an issue with um
  82. actually accessing that population getting drugs out to them it is it is in fact most of the uh presentations that
  83. you are seeing today uh show that 60 to 70% of the population in India does not have access to medicines of the
  84. Physicians uh so that's a huge challenge India is 13th largest pharmaceutical Market by value and
  85. fourth largest by volume it is has the lowest prices in the world and the latest medicines in the world available
  86. at those low prices and yet more than 60% of population does not have access to medicines and that's some things
  87. which got to change if if U I think government industry everybody needs to look at it completely
  88. differently if that has to change and access to medicine has to improve what kinds of moves are companies like Lally
  89. making towards changing that ili there's working on some specific therapeutic areas as far as that is
  90. concerned and I would single out diabetes uh Lily was the first company in the world in 1923 to launch insulin
  91. you know discovered by Dr Banting and Dr best and India and China between them have the highest number of diabetics in
  92. the world and making low price insulin available that's one thing but it's more about the awareness the education the
  93. diagnosis of diabetes and you cannot treat diabetes only by insulin insulin is in fact a drug of The Last Resort you
  94. start by diet by exercise uh then you go on to the oral tablets and so on and that's an area where Lily is making
  95. significant efforts in both the countries India and China to raise the awareness awareness level the education
  96. level and making sure that you are diagnosed early and and you are able to take care of it so that you don't even
  97. need insulin in the or maybe you can delay uh using medicines for for a while right right well thanks very much for
  98. speaking with us today it's a pleasure to be here as I said thank you for more information please visit
  99. knowledge. won. up.edu India

Brief Summary

Rajiv Gulati discusses Eli Lilly's strategies in India and China, joint ventures, and access to medicines in the pharmaceutical industry.

Key points

  • Eli Lilly's Market Strategies. Eli Lilly adapts its strategies for China and India, focusing on local strengths.
  • Challenges in Indian Pharmaceutical Market. Over 60% of India's population lacks access to medicines despite low prices.

Tension

45/ 100Some tension

Related episodes